vs
CRA INTERNATIONAL, INC.（CRAI）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是CRA INTERNATIONAL, INC.的1.1倍（$207.3M vs $197.0M），CRA INTERNATIONAL, INC.净利率更高（6.7% vs -62.0%，领先68.7%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 11.6%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 7.1%）
CRA International是一家全球性咨询企业，总部位于美国波士顿，核心业务涵盖专家证言、诉讼支持、战略咨询与商业分析等领域，服务对象包括律师事务所、各类企业、会计师事务所以及政府部门。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CRAI vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $197.0M | $207.3M |
| 净利润 | $13.2M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 10.5% | -54.7% |
| 净利率 | 6.7% | -62.0% |
| 营收同比 | 11.6% | 25.9% |
| 净利润同比 | -12.0% | 3.5% |
| 每股收益（稀释后） | $1.99 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $197.0M | $207.3M | ||
| Q3 25 | $185.9M | $159.9M | ||
| Q2 25 | $186.9M | $166.5M | ||
| Q1 25 | $181.9M | $139.3M | ||
| Q4 24 | $176.4M | $164.6M | ||
| Q3 24 | $167.7M | $139.5M | ||
| Q2 24 | $171.4M | $147.0M | ||
| Q1 24 | $171.8M | $108.8M |
| Q4 25 | $13.2M | $-128.6M | ||
| Q3 25 | $11.5M | $-180.4M | ||
| Q2 25 | $12.1M | $-115.0M | ||
| Q1 25 | $18.0M | $-151.1M | ||
| Q4 24 | $15.0M | $-133.2M | ||
| Q3 24 | $11.4M | $-133.5M | ||
| Q2 24 | $6.5M | $-131.6M | ||
| Q1 24 | $13.7M | $-170.7M |
| Q4 25 | 10.5% | -54.7% | ||
| Q3 25 | 9.3% | -106.9% | ||
| Q2 25 | 10.6% | -64.8% | ||
| Q1 25 | 14.0% | -102.6% | ||
| Q4 24 | 12.2% | -74.3% | ||
| Q3 24 | 11.0% | -94.6% | ||
| Q2 24 | 6.6% | -79.1% | ||
| Q1 24 | 11.4% | -151.9% |
| Q4 25 | 6.7% | -62.0% | ||
| Q3 25 | 6.2% | -112.8% | ||
| Q2 25 | 6.5% | -69.0% | ||
| Q1 25 | 9.9% | -108.5% | ||
| Q4 24 | 8.5% | -80.9% | ||
| Q3 24 | 6.8% | -95.7% | ||
| Q2 24 | 3.8% | -89.5% | ||
| Q1 24 | 8.0% | -156.8% |
| Q4 25 | $1.99 | $-1.28 | ||
| Q3 25 | — | $-1.81 | ||
| Q2 25 | — | $-1.17 | ||
| Q1 25 | — | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | — | $-1.40 | ||
| Q2 24 | — | $-1.52 | ||
| Q1 24 | — | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $18.2M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $213.6M | $-80.0M |
| 总资产 | $628.9M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $18.2M | $421.0M | ||
| Q3 25 | $22.5M | $202.5M | ||
| Q2 25 | $19.4M | $176.3M | ||
| Q1 25 | $25.6M | $127.1M | ||
| Q4 24 | $26.7M | $174.0M | ||
| Q3 24 | $24.5M | $150.6M | ||
| Q2 24 | $24.6M | $480.7M | ||
| Q1 24 | $37.1M | $112.3M |
| Q4 25 | $213.6M | $-80.0M | ||
| Q3 25 | $201.7M | $9.2M | ||
| Q2 25 | $197.0M | $151.3M | ||
| Q1 25 | $227.3M | $144.2M | ||
| Q4 24 | $212.1M | $255.0M | ||
| Q3 24 | $204.5M | $346.8M | ||
| Q2 24 | $191.7M | $432.4M | ||
| Q1 24 | $211.8M | $140.3M |
| Q4 25 | $628.9M | $1.5B | ||
| Q3 25 | $629.0M | $1.2B | ||
| Q2 25 | $606.8M | $1.3B | ||
| Q1 25 | $590.4M | $1.3B | ||
| Q4 24 | $571.4M | $1.5B | ||
| Q3 24 | $582.3M | $1.5B | ||
| Q2 24 | $546.0M | $1.6B | ||
| Q1 24 | $552.5M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $22.4M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 1.70× | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $22.4M | $-99.8M | ||
| Q3 25 | $36.5M | $-91.4M | ||
| Q2 25 | $5.9M | $-108.3M | ||
| Q1 25 | $-80.0M | $-166.5M | ||
| Q4 24 | $79.4M | $-79.3M | ||
| Q3 24 | $31.6M | $-67.0M | ||
| Q2 24 | $1.8M | $-77.0M | ||
| Q1 24 | $-63.1M | $-190.7M |
| Q4 25 | — | $-100.8M | ||
| Q3 25 | $35.9M | $-92.7M | ||
| Q2 25 | $4.7M | $-110.7M | ||
| Q1 25 | $-81.0M | $-167.8M | ||
| Q4 24 | $68.8M | $-79.5M | ||
| Q3 24 | $28.6M | $-68.6M | ||
| Q2 24 | $-509.0K | $-79.0M | ||
| Q1 24 | $-63.8M | $-193.9M |
| Q4 25 | — | -48.6% | ||
| Q3 25 | 19.3% | -58.0% | ||
| Q2 25 | 2.5% | -66.5% | ||
| Q1 25 | -44.5% | -120.5% | ||
| Q4 24 | 39.0% | -48.3% | ||
| Q3 24 | 17.0% | -49.2% | ||
| Q2 24 | -0.3% | -53.7% | ||
| Q1 24 | -37.1% | -178.2% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | 0.3% | 0.8% | ||
| Q2 25 | 0.6% | 1.5% | ||
| Q1 25 | 0.5% | 1.0% | ||
| Q4 24 | 6.0% | 0.1% | ||
| Q3 24 | 1.8% | 1.2% | ||
| Q2 24 | 1.4% | 1.4% | ||
| Q1 24 | 0.4% | 3.0% |
| Q4 25 | 1.70× | — | ||
| Q3 25 | 3.19× | — | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | -4.44× | — | ||
| Q4 24 | 5.30× | — | ||
| Q3 24 | 2.76× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | -4.61× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRAI
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
